Thymoquinone-based nanotechnology for cancer therapy: promises and challenges

被引:51
作者
Ballout, Farah [1 ,2 ]
Habli, Zeina [1 ,2 ]
Rahal, Omar Nasser [3 ]
Fatfat, Maamoun [1 ,2 ]
Gali-Muhtasib, Hala [1 ,2 ,4 ,5 ]
机构
[1] Amer Univ Beirut, Dept Biol, Beirut 1103, Lebanon
[2] Amer Univ Beirut, Dept Anat Cell Biol & Physiol Sci, Beirut 1103, Lebanon
[3] Saba Univ, Sch Med, Saba, Dutch Caribbean, Netherlands
[4] Amer Univ Beirut, Fac Arts & Sci, Dept Biol, Beirut, Lebanon
[5] Amer Univ Beirut, Ctr Drug Discovery, Fac Med, Beirut, Lebanon
关键词
NANOSTRUCTURED LIPID CARRIERS; DRUG-DELIVERY SYSTEMS; BREAST-CANCER; ANTICANCER ACTIVITY; IN-VITRO; ORAL BIOAVAILABILITY; NANOPARTICLES; TOXICITY; TRIAL; NIOSOMES;
D O I
10.1016/j.drudis.2018.01.043
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Thymoquinone (TQ), the active ingredient of black seed, is a promising anticancer molecule that inhibits cancer cell growth and progression in vitro and in vivo. Despite the promising anticancer activities of TQ its translation to the clinic is limited by its poor bioavailability and hydrophobicity. As such, we and others encapsulated TQ in nanoparticles to improve its delivery and limit undesirable cytotoxicity. These TQ-nanoparticle formulations showed improved anticancer and anti-inflammatory activities when compared with free TQ. Here, we provide an overview of the various TQ-nanoparticle formulations, highlight their superior efficacy and discuss up-to-date solutions to further enhance TQ bioavailability and anticancer activity, thus improving potential for clinical translation.
引用
收藏
页码:1089 / 1098
页数:10
相关论文
共 73 条
[1]   Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration [J].
Abdelwahab, Siddig Ibrahim ;
Sheikh, Bassem Yousef ;
Taha, Manal Mohamed Elhassan ;
How, Chee Wun ;
Abdullah, Rasedee ;
Yagoub, Umar ;
El-Sunousi, Rashad ;
Eid, Eltayeb E. M. .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2013, 8 :2163-2172
[2]   Preparation, characterization and antiproliferative activity of thymoquinone-β-cyclodextrin self assembling nanoparticles [J].
Abu-Dahab, R. ;
Odeh, F. ;
Ismail, S. I. ;
Azzam, H. ;
Al Bawab, A. .
PHARMAZIE, 2013, 68 (12) :939-944
[3]   The Effect of Route of Administration in Thymoquinone Toxicity in Male and Female Rats [J].
AbuKhader, M. M. .
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 74 (03) :195-200
[4]  
Al-Amri A. M., 2009, Shiraz E Medical Journal, V10, P107
[5]   Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study [J].
Alam, Sanjar ;
Khan, Zeenat I. ;
Mustafa, Gulam ;
Kumar, Manish ;
Islam, Fakhrul ;
Bhatnagar, Aseem ;
Ahmad, Farhan J. .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2012, 7 :5705-5718
[6]   Pharmacokinetic plasma behaviors of intravenous and oral bioavailability of thymoquinone in a rabbit model [J].
Alkharfy, Khalid M. ;
Ahmad, Ajaz ;
Khan, Rao M. A. ;
Al-Shagha, Waleed M. .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2015, 40 (03) :319-323
[7]  
[Anonymous], ASIAN PAC J CANCER P, DOI DOI 10.7314/APJCP.2014.15.1.221
[8]   A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [J].
Autio, Karen A. ;
Garcia, Jorge A. ;
Alva, Ajjai Shivaram ;
Hart, Lowell L. ;
Milowsky, Matthew I. ;
Posadas, Edwin M. ;
Ryan, Charles J. ;
Summa, Jason Mark ;
Youssoufian, Hagop ;
Scher, Howard I. ;
Dreicer, Robert .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[9]   Structure-Activity Studies on Therapeutic Potential of Thymoquinone Analogs in Pancreatic Cancer [J].
Banerjee, Sanjeev ;
Azmi, Asfar S. ;
Padhye, Subhash ;
Singh, Marjit W. ;
Baruah, Jubaraj B. ;
Philip, Philip A. ;
Sarkar, Fazlul H. ;
Mohammad, Ramzi M. .
PHARMACEUTICAL RESEARCH, 2010, 27 (06) :1146-1158
[10]   Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method [J].
Barichello, JM ;
Morishita, M ;
Takayama, K ;
Nagai, T .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (04) :471-476